On November 9, 2022 Sysmex reported that Summary of Consolidated Financial Results [ IFRS ] for the First Six Months of the Fiscal Year Ending March 31, 202 (Press release, Sysmex, NOV 9, 2022, View Source [SID1234623647])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
1. Results for the First Six Months of the Fiscal Year Ending March 31, 2023
(1) Operating results
(2) Financial condition
2. Dividend
3. Financial Forecast for the Year Ending March 31, 2023
4. Other Information
(1) Changes in significant consolidated subsidiaries (which resulted in changes in scope of consolidation): Yes Excluded: One company (Sysmex International Reagents Co., Ltd.)
(2) Changes in accounting policies and accounting estimates 1) Changes in accounting policies required by IFRS: No 2) Other changes in accounting policies:
No 3) Changes in accounting estimates:
No (3) Number of outstanding stock (common stock) 1) Number of outstanding stock at the end of each fiscal period (including treasury stock): 209,675,082 shares as of Sep. 30, 2022; 209,657,362 shares as of Mar. 31, 2022 2) Number of treasury stock at the end of each fiscal period: 447,308 shares as of Sep. 30, 2022; 447,255 shares as of Mar. 31, 2022 3) Average number of outstanding stock for each period (cumulative): 209,218,108 shares for the six months ended Sep. 30, 2022 209,014,581 shares for the six months ended Sep. 30, 2021